
---
title: '诱饵纳米粒子在冠状病毒进化过程中欺骗它'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/20/100217j6gz9d9x84g8d89o.jpg'
author: 科学网
comments: false
date: Wed, 20 Apr 2022 10:08:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/20/100217j6gz9d9x84g8d89o.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-family: "times new roman"; font-size: 24px;"><span style="font-family: "times new roman";">克服</span> COVID <span style="font-family: "times new roman";">变种：诱饵纳米粒子在冠状病毒进化过程中欺骗它</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="text-align: center;"><a href="https://scitechdaily.com/images/Decoy-Particles-Trick-Coronavirus-As-It-Evolves-scaled.jpg" target="_blank"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/20/100217j6gz9d9x84g8d89o.jpg" title alt="Decoy-Particles-Trick-Coronavirus-As-It-Evolves-scaled.jpg" referrerpolicy="no-referrer"></a><br></p><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 1 </span><span style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank">Credit: Taylor Gunnels</a></span></p><table><tbody><tr class="firstRow"><td valign="top" style="border-width: 1px; border-color: windowtext; padding: 0px 7px; word-break: break-all; text-align: center;"><a href="https://scitechdaily.com/images/Josh-Leonard.jpg" target="_blank"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/20/100311c6u7slhl9llz62rp.jpg" title alt="Josh-Leonard.jpg" referrerpolicy="no-referrer"></a><p><br></p></td><td valign="top" style="border-top-width: 1px; border-right-width: 1px; border-bottom-width: 1px; border-top-color: windowtext; border-right-color: windowtext; border-bottom-color: windowtext; border-left: none; padding: 0px 7px; word-break: break-all; text-align: center;"><a href="https://scitechdaily.com/images/Neha-Kamat.jpg" target="_blank"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/20/100324ukbi2p8o5ep8zowx.jpg" title alt="Neha-Kamat.jpg" referrerpolicy="no-referrer"></a><p><br></p></td></tr><tr><td valign="top" style="border-right-width: 1px;border-bottom-width: 1px;border-left-width: 1px;border-right-color: windowtext;border-bottom-color: windowtext;border-left-color: windowtext;border-top: none;padding: 0 7px"><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 2 </span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Leonard%2C+Joshua+N" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Joshua   N. Leonard</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">约书亚</span>·<span style="font-size: 18px; font-family: 宋体;">伦纳德</span></span></p></td><td valign="top" style="border-top: none;border-left: none;border-bottom-width: 1px;border-bottom-color: windowtext;border-right-width: 1px;border-right-color: windowtext;padding: 0 7px"><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 3 </span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Kamat%2C+Neha+P" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Neha   P. Kamat</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">内哈</span>·<span style="font-size: 18px; font-family: 宋体;">卡马特</span></span></p></td></tr></tbody></table><p style="line-height: 2em; text-align: left;"><span style="font-size: 18px; font-family: "times new roman";">新冠疫情大流行几年来，不仅全球蔓延，而且其病毒变异不断。面对新冠病毒的新变异体，如何进行有效防控是全球防疫工作所面临的严峻挑战。据美国</span><a href="https://scitechdaily.com/tag/northwestern-university/" style="font-size: 18px; font-family: "times new roman";" target="_blank">西北大学</a><span style="font-size: 18px; font-family: "times new roman";">（</span><a href="https://scitechdaily.com/tag/northwestern-university/" style="font-size: 18px; font-family: "times new roman";" target="_blank">Northwestern University</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）</span>2022<span style="font-family: 宋体;">年</span>4<span style="font-family: 宋体;">月</span>16<span style="font-family: 宋体;">日提供的新消息，新兴疗法可以克服耐药变异。</span></span><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">它们可能看起来像细胞，行为也像细胞。但一种新的潜在</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">治疗方法实际上是一个巧妙伪装的骗子，它会吸引新冠病毒并结合它们，使其失去活性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">随着不断发展的</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">病毒开始逃避曾经有希望的治疗方法，例如单克隆抗体疗法，研究人员对这些</span>“<span style="font-size: 18px; font-family: 宋体;">诱饵</span>”<span style="font-size: 18px; font-family: 宋体;">纳米粒子越来越感兴趣。模拟常规细胞，诱饵纳米粒子像海绵一样吸收相关病毒，抑制它们感染身体的其他部位。相关研究结果于</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>4<span style="font-size: 18px; font-family: 宋体;">月</span>7<span style="font-size: 18px; font-family: 宋体;">日已经在</span></span><a href="https://doi.org/10.1002/smll.202200125" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Small</span></a><span style="font-size: 18px; font-family: "times new roman";">杂志网站发表——</span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Gunnels%2C+Taylor+F" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Taylor F. Gunnels</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Stranford%2C+Devin+M" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Devin M. Stranford</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Mitrut%2C+Roxana+E" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Roxana E. Mitrut</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Kamat%2C+Neha+P" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Neha P. Kamat</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://onlinelibrary.wiley.com/action/doSearch?ContribAuthorRaw=Leonard%2C+Joshua+N" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Joshua N. Leonard</span></a><span style="font-size: 18px; font-family: "times new roman";">. Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 Infection. </span><a href="https://doi.org/10.1002/smll.202200125" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Small</span></a><span style="font-size: 18px; font-family: "times new roman";">, 2022, </span><a href="https://doi.org/10.1002/smll.202200125" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1002/smll.202200125</span></a><span style="font-size: 18px; font-family: "times new roman";">. First published: 07 April 2022. </span><a href="https://onlinelibrary.wiley.com/doi/10.1002/smll.202200125" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">https://onlinelibrary.wiley.com/doi/10.1002/smll.202200125</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在此项新研究中，西北大学合成生物学家着手阐明使诱饵纳米粒子有效并能抵抗病毒逃逸所需的设计规则。在设计和测试各种迭代之后，研究人员确定了一组广泛的诱饵</span>——<span style="font-size: 18px; font-family: 宋体;">所有诱饵都可以使用不同的方法制造</span>——<span style="font-size: 18px; font-family: 宋体;">它们对原始病毒和突变变体都非常有效。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">事实上，与传统的基于蛋白质的抑制剂药物相比，诱饵纳米粒子在抑制自然发生的病毒突变体方面的效率高达</span>50<span style="font-size: 18px; font-family: 宋体;">倍。当针对旨在抵抗此类治疗的病毒突变体进行测试时，诱饵纳米粒子在抑制感染方面的效率提高了</span>1500<span style="font-size: 18px; font-family: 宋体;">倍。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">尽管需要进行更多的研究和临床评估，但研究人员认为，有朝一日，诱饵纳米粒子输液可能会用于治疗患有严重或长期病毒感染的患者。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在该论文中，该团队在细胞培养物中测试了诱饵纳米粒子对抗亲本</span> SARS-CoV-2 <span style="font-size: 18px; font-family: 宋体;">病毒和五种变体包括</span>beta<span style="font-size: 18px; font-family: 宋体;">（</span>β<span style="font-size: 18px; font-family: 宋体;">）、</span>delta<span style="font-size: 18px; font-family: 宋体;">（</span>δ<span style="font-size: 18px; font-family: 宋体;">）、</span>delta-plus<span style="font-size: 18px; font-family: 宋体;">（</span>δ+<span style="font-size: 18px; font-family: 宋体;">）</span> <span style="font-size: 18px; font-family: 宋体;">和</span> lambda<span style="font-size: 18px; font-family: 宋体;">（</span>λ<span style="font-size: 18px; font-family: 宋体;">）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">该研究的共同通讯作者、西北大学的约书亚·伦纳德（</span>Fig. 2<span style="font-size: 18px; font-family: 宋体;">）说：</span>“<span style="font-size: 18px; font-family: 宋体;">我们证明诱饵纳米粒子是所有这些不同病毒变体的有效抑制剂。即使是逃脱其他药物的变体也没有逃脱我们的诱饵纳米颗粒。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">该研究的共同通讯作者、西北大学的内哈</span>·<span style="font-size: 18px; font-family: 宋体;">卡马特</span>(Fig. 3)<span style="font-size: 18px; font-family: 宋体;">补充道：</span>“<span style="font-size: 18px; font-family: 宋体;">当我们进行这项研究时，世界各地不断出现不同的变体。我们一直在针对新变种测试我们的诱饵，它们一直是可行的，而且非常有效。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">约书亚·伦纳德是西北大学麦考密克工程学院</span>(<span style="font-family: "times new roman"; font-size: 18px; color: blue;">Northwestern’s McCormick School of Engineering)</span><span style="font-size: 18px; font-family: 宋体;">的化学和生物工程</span>(<span style="font-family: "times new roman"; font-size: 18px; color: blue;">chemical and biological engineering)</span><span style="font-size: 18px; font-family: 宋体;">副教授。内哈</span>·<span style="font-size: 18px; font-family: 宋体;">卡马特是西北大学麦考密克工程学院的生物医学工程助理教授。两人都是西北大学合成生物学中心</span>(<span style="font-family: "times new roman"; font-size: 18px; color: blue;">Northwestern’s Center for Synthetic Biology)</span><span style="font-size: 18px; font-family: 宋体;">的主要成员。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>“</strong><strong><span style="font-size: 18px; font-family: 宋体;">进化摇滚和一个艰难的地方</span>'(<span style="font-family: "times new roman"; font-size: 18px; color: blue;">Evolutionary rock and a hard place)”</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">随着</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">病毒发生变异以产生新的变体，一些治疗方法在对抗不断发展的病毒方面变得不那么有效。</span></span><a href="https://abcnews.go.com/Health/feds-halt-monoclonal-treatment-ba2-concerns/story?id=83895502" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">就在上个月</span></a><span style="font-size: 18px; font-family: "times new roman";">(<span style="font-family: "times new roman"; font-size: 18px; color: blue;"><a href="https://abcnews.go.com/Health/feds-halt-monoclonal-treatment-ba2-concerns/story?id=83895502" target="_blank">Just last month</a>)</span><span style="font-size: 18px; font-family: 宋体;">，美国食品和药物管理局</span> (FDA) <span style="font-size: 18px; font-family: 宋体;">暂停了几种单克隆抗体治疗，例如，由于它们对新冠病毒变种奥密克戎</span>(</span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">omicron</span></a><span style="font-size: 18px; font-family: "times new roman";">)<span style="font-size: 18px; font-family: 宋体;">的亚变种之一</span>BA.2<span style="font-size: 18px; font-family: 宋体;">（</span><span style="font-family: "times new roman"; font-size: 18px; color: blue;">BA.2 omicron subvariant</span><span style="font-size: 18px; font-family: 宋体;">）的失败。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">但即使治疗失败，新研究中的诱饵纳米粒子也从未失去效力。约书亚·伦纳德说，这是因为诱饵将</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">置于</span>“<span style="font-size: 18px; font-family: 宋体;">进化的岩石和坚硬的地方之间</span>”<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">通过将其臭名昭著的刺突蛋白与人类血管紧张素转换酶</span>2(</span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">angiotensin-converting enzyme 2</span></a> <span style="font-size: 18px; font-family: "times new roman";">简称</span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">ACE2</span></a><span style="font-size: 18px; font-family: "times new roman";">) <span style="font-size: 18px; font-family: 宋体;">受体结合来感染人类细胞。</span></span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">ACE2</span></a><span style="font-size: 18px; font-family: "times new roman";">是细胞表面的一种蛋白质，为病毒提供了一个切入点。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">为了设计诱饵纳米粒子，西北大学的团队使用了从所有细胞类型中自然释放的纳米级粒子——细胞外囊泡（</span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">extracellular vesicles</span></a><span style="font-size: 18px; font-family: "times new roman";">）。他们设计了产生这些颗粒的细胞，以过度表达</span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">ACE2</span></a> <span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">基因，从而在颗粒表面产生许多</span>ACE2<span style="font-size: 18px; font-family: 宋体;">受体。当病毒与诱饵接触时，它会与这些受体紧密结合，而不是与真实细胞结合，从而使病毒无法感染细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">约书亚·伦纳德说：</span>“<span style="font-size: 18px; font-family: 宋体;">要让病毒进入细胞，它必须与</span>ACE2<span style="font-size: 18px; font-family: 宋体;">受体结合。诱饵纳米粒子对</span> SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">提出了进化挑战。病毒必须想出一种完全不同的方式进入细胞，以避免需要使用</span>ACE2<span style="font-size: 18px; font-family: 宋体;">受体。没有明显的进化逃生路线。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">未来的益处（</span></strong><strong><span style="font-size: 18px; font-family: 宋体;"></span></strong><strong><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" target="_blank">Future benefits</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">除了有效对抗耐药病毒外，诱饵纳米粒子还有其他几个好处。因为它们是生物（而不是合成）材料，纳米颗粒不太可能引发免疫反应，从而引起炎症并干扰药物的功效。它们还表现出低毒性，使它们特别适合用于治疗重症患者的持续或重复给药。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">当</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">大流行开始时，研究人员和临床医生在发现病毒和开发治疗它的新药之间经历了令人不安的差距。对于下一次大流行，诱饵纳米粒子可以在疫苗研制出来之前提供一种快速、有效的治疗方法。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">约书亚·伦纳德说：</span>“<span style="font-size: 18px; font-family: 宋体;">诱饵策略是你可以尝试的最直接的事情之一，一旦你知道病毒使用的受体，你就可以开始用这些受体构建诱饵粒子。在未来病毒大流行的关键早期阶段，我们可能会快速跟踪这样的方法，以减少严重的疾病和死亡。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">该研究得到了美国国家科学基金会（</span>National Science Foundation grant numbers 1844219 and 1844336<span style="font-size: 18px; font-family: 宋体;">）和凯洛合资企业</span>(Kairos Ventures)<span style="font-size: 18px; font-family: 宋体;">的支持。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://onlinelibrary.wiley.com/doi/10.1002/smll.202200125" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://scitechdaily.com/overcoming-covid-variants-decoy-nanoparticles-trick-coronavirus-as-it-evolves/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://doi.org/10.1002/smll.202200125" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">The ability of pathogens to develop drug resistance is a global health challenge. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an urgent need wherein several variants of concern resist neutralization by monoclonal antibody (mAb) therapies and vaccine-induced sera. Decoy nanoparticles—cell-mimicking particles that bind and inhibit virions—are an emerging class of therapeutics that may overcome such drug resistance challenges. To date, quantitative understanding as to how design features impact performance of these therapeutics is lacking. To address this gap, this study presents a systematic, comparative evaluation of various biologically derived nanoscale vesicles, which may be particularly well suited to sustained or repeated administration in the clinic due to low toxicity, and investigates their potential to inhibit multiple classes of model SARS-CoV-2 virions. A key finding is that such particles exhibit potent antiviral efficacy across multiple manufacturing methods, vesicle subclasses, and virus-decoy binding affinities. In addition, these cell-mimicking vesicles effectively inhibit model SARS-CoV-2 variants that evade mAbs and recombinant protein-based decoy inhibitors. This study provides a foundation of knowledge that may guide the design of decoy nanoparticle inhibitors for SARS-CoV-2 and other viral infections.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1334771.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1334771.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1334672.html" target="_black">源自甘草的物质可能具有抗炎和抗癌作用</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-212210-1334919.html" target="_black">中巴美合作研究表明，手性金纳米颗粒可使疫苗效力提高25%以上</a>                    <!--大赛结束-->
                                        
  
</div>
            